DUSP16 and squamous cell carcinoma: To test our hypothesis that strong DUSP16 expression is associated with poor survival in a patient population, we performed clinicopathological analysis on locally advanced squamous cell carcinoma (SCC) of the head and neck (HNSCC) cohort where concurrent single-agent cisplatin treatment with radiotherapy is the standard first-line regime.